Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW PEDINOFF

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1033116801
CMS profile
364149
Location
SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$282.79

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $282.79 24

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW PEDINOFF

NPI 1033116801 · CMS profile ID 364149

Allopathic & Osteopathic Physicians / Allergy & Immunology

SKILLMAN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033116801?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033116801?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033116801?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANDREW PEDINOFF, NPI 1033116801, CMS profile ID 364149, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1033116801?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $282.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $15.2711/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977223 CMS
Regeneron Healthcare Solutions, Inc. $13.9010/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927320097 CMS
GlaxoSmithKline, LLC. $2.5410/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977203 CMS
GlaxoSmithKline, LLC. $12.5010/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977213 CMS
GlaxoSmithKline, LLC. $4.8309/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977221 CMS
GlaxoSmithKline, LLC. $13.4709/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977219 CMS
GlaxoSmithKline, LLC. $9.5008/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977215 CMS
GlaxoSmithKline, LLC. $12.0008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977209 CMS
GlaxoSmithKline, LLC. $2.2008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977217 CMS
LEO Pharma Inc. $13.3808/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936266609 CMS
kaleo, Inc. $13.8006/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941008353 CMS
GlaxoSmithKline, LLC. $13.3306/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977225 CMS
Regeneron Healthcare Solutions, Inc. $14.3306/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927320091 CMS
GlaxoSmithKline, LLC. $14.3405/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977207 CMS
GlaxoSmithKline, LLC. $13.2504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977205 CMS
Covis Pharma GmBH $16.2603/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953396493 CMS
AstraZeneca Pharmaceuticals LP $13.5803/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914816855 CMS
GlaxoSmithKline, LLC. $12.6402/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977211 CMS
GlaxoSmithKline, LLC. $1.3102/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944977227 CMS
Regeneron Healthcare Solutions, Inc. $14.2102/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927320087 CMS
AstraZeneca Pharmaceuticals LP $14.9902/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915101917 CMS
Novartis Pharmaceuticals Corporation $12.1101/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894221337 CMS
Regeneron Healthcare Solutions, Inc. $14.9301/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927320081 CMS
AstraZeneca Pharmaceuticals LP $14.1201/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914742827 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $14.87 1
PY2021 $2,610.81 21
PY2022 $282.79 24
PY2023 $186.57 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,078.66 3
PY2023 Principal investigator $155,562.82 28
PY2022 Principal investigator $467,597.19 23
PY2021 Principal investigator $355,310.51 36
PY2020 Principal investigator $554,325.08 51
PY2019 Principal investigator $722,989.71 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $8,362.03 12/31/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330327
Principal investigator 1 Allergan, Inc. $250.00 12/31/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330329
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,045.18 12/31/2020 Non-covered Recipient Entity
Princeton Center For Clinical
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736749953
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,410.88 12/31/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740110995
Principal investigator 1 Allergan, Inc. $21,925.05 12/23/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330325
Principal investigator 1 Hikma Pharmaceuticals USA $3,000.00 12/11/2020 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 717234409
Principal investigator 1 Amphastar Pharmaceuticals, Inc. $221,782.81 12/03/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
Phamacodynamic (PD) Bronchodilatation Bioequivalence (BE) Study of Albuterol Sulfate HFA MDI 90 mcg/inhalation in Asthma Patients No dispute reported 06/30/2026 745335541
Principal investigator 1 CIPLA USA INC. $1,125.86 12/03/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145375
Principal investigator 1 Allergan, Inc. $16,247.85 11/23/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330323
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,693.00 11/19/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. No dispute reported 06/30/2026 721490961
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,300.00 11/12/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105749
Principal investigator 1 Allergan, Inc. $14,706.00 10/23/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330321
Principal investigator 1 Allergan, Inc. $327.00 10/20/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721304275
Principal investigator 1 CIPLA USA INC. $1,003.64 10/19/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145335
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,640.00 10/08/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105699
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $700.00 10/08/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105701
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,750.00 10/08/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105703
Principal investigator 1 Allergan, Inc. $169.00 09/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721299733
Principal investigator 1 Allergan, Inc. $6,500.00 09/11/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330319
Principal investigator 1 Allergan, Inc. $500.00 09/10/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 721330317
Principal investigator 1 Allergan, Inc. $2,518.65 08/13/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330315
Principal investigator 1 CIPLA USA INC. $29,010.00 08/03/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145429
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,810.00 07/24/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105653
Principal investigator 1 Allergan, Inc. $3,835.55 07/14/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330313
Principal investigator 1 CIPLA USA INC. $19,405.46 07/13/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145301
Principal investigator 1 CIPLA USA INC. $5,407.97 07/06/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145109
Principal investigator 1 CIPLA USA INC. $2,090.44 07/06/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145139
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 05/28/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105621
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 05/21/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740110993
Principal investigator 1 Allergan, Inc. $3,337.35 05/14/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330311
Principal investigator 1 Allergan, Inc. $600.00 05/11/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330309
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,251.00 04/27/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740110991
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,500.00 04/17/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105567
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,435.68 04/16/2020 Non-covered Recipient Entity
PRINCETON ALLERGY AND ASTHMA ASSOCIATES PA
A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA No dispute reported 06/30/2026 721494675
Principal investigator 1 Allergan, Inc. $3,718.30 04/14/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330307
Principal investigator 1 CIPLA USA INC. $2,250.00 04/13/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751144899
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,000.00 04/06/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105533
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 04/06/2020 Non-covered Recipient Entity
CRN Clinical Research Network
A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma No dispute reported 06/30/2026 740105535
Principal investigator 1 CIPLA USA INC. $28,988.22 03/19/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145167
Principal investigator 1 CIPLA USA INC. $43,507.39 03/19/2020 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751145211
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,580.00 03/18/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740110989
Principal investigator 1 Allergan, Inc. $4,952.35 03/16/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330305
Principal investigator 1 CIPLA USA INC. $1,060.92 02/27/2020 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, 4-WEEK CLINICAL ENDPOINT BIOEQUIVALENCE STUDY COMPARING FLUTICASONE PROPIONATE/SALMETEROL 100/50 MICRO GM INHALATION POWDER WITH ADVAIR DISKUS 100/50 MICRO GM IN ASTHMA PATIENTS No dispute reported 06/30/2026 751144979
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,850.00 02/21/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740110987
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,389.10 02/18/2020 Non-covered Recipient Entity
Princeton Center For Clinical
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736739907
Principal investigator 1 Allergan, Inc. $6,446.70 02/14/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330303
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,930.00 01/28/2020 Non-covered Recipient Entity
Princeton Center for Clinical Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740110985
Principal investigator 1 Hikma Pharmaceuticals USA $3,433.75 01/20/2020 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 717234407
Principal investigator 1 Allergan, Inc. $86.00 01/14/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721247037
Principal investigator 1 Allergan, Inc. $8,729.55 01/14/2020 Non-covered Recipient Entity
PRINCETON CTR FOR CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE LONGTERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721330301
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,762.40 01/01/2020 Non-covered Recipient Entity
PRINCETON CENTER FOR CLINICAL RESEARCH
A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD-OF-CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 721494679